NeuroAge Therapeutics unveiled its NeuroAge Test, a comprehensive brain ageing assessment that combines advanced AI, MRI technology, genetic and cognitive analysis to predict biological brain age and dementia risk up to 30 years before symptoms appear.
By providing personalised reports and a dashboard with actionable recommendations, it enables users to optimise brain function and reduce neurodegenerative risk, promoting long-term cognitive health.
“The NeuroAge Test represents a significant breakthrough in how we approach brain aging,” said Dr. Christin Glorioso, CEO and co-founder of NeuroAge Therapeutics.
“Our test empowers individuals to take control of their cognitive health by giving them the data-driven insights they need to maintain optimal brain function as they age.”
The global impact of dementia is staggering, with more than 55 million people worldwide living with the condition. Alzheimer’s disease accounts for 60 to 70 per cent of these cases, and the risk of developing dementia doubles approximately every five years after age 65.
The NeuroAge Test aims to identify early markers of cognitive decline, allowing for earlier intervention and better management of brain health.
The NeuroAge Test uniquely identifies three distinct types of brain aging: structural, functional, and molecular.
By assessing a comprehensive panel of advanced biomarkers, the test provides individuals with a detailed understanding of their brain health status and personalised insights to guide proactive interventions.
Key Features of the NeuroAge Test also include interactive challenges evaluating memory, attention, and processing speed, examination of 52 RNA levels of genes in the blood that are predictive of brain ageing, whole genome DNA testing with screening for more than 300 neurodegenerative disease genetic markers, including for rare familial mutations for Alzheimer’s, Parkinson’s, Vascular Dementia, and advanced imaging offering a 3D view of cognitive health.
